What to know about Alnylam’s upcoming readout on its heart drug

Taking stock of the drug industry, from the lab to the medicine chest

August 20, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | What to know about Alnylam's upcoming readout on its heart drug  The results of the HELIOS-B trial could affect care — and impact the stock prices of Pfizer and BridgeBio, which offer competing therapies By Elaine Chen, Andrew Joseph, and Adam Feuerstein STAT+ | Lilly's Zepbound slashed risk of developing diabetes Eli Lilly's weight loss drug significantly cut the risk of developing diabetes, showing the benefits of long-term use of the therapy. By Elaine Chen STAT+ | Congressional probe questions clinical trials run in China, citing army involvement A new inquiry, about possible projects with the People's Liberation Army, jeopardizes another aspect of drugmakers' actions in China. By John Wilkerson Adobe STAT+ | Q&A: How the FDA could use AI for drug and device safety surveillance Researchers suggest FDA could use artificial intelligence to enhance Sentinel, the agency's safety surveillance system for drugs and devices. By Mohana Ravindranath Opinion: Improving the FDA-EMA parallel scientific advice program to advance complex generics The FDA and EMA launched a parallel scientific advice pilot program for complex generics products. It's good, but it could be better. By Michael Banks

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser